The Secretary for Health, Professor Lo Chung-mau, met with the Director of the Development and Reform Commission of Shenzhen Municipality, Dr Guo Ziping, today (April 23) to have an in-depth exchange on areas such as the development of Chinese and Western medicine and medical devices in the two places.  

     Professor Lo said at the meeting, "The Resolution of the Central Committee of the Communist Party of China (CPC Central Committee) on Further Deepening Reform Comprehensively to Advance Chinese Modernization adopted by the Third Plenary Session of the 20th CPC Central Committee pointed out the need of further reforming the medical and healthcare systems, and improving the mechanisms for supporting the development of innovative drugs and medical equipment. The Hong Kong Special Administrative Region (HKSAR) Government strenuously works in line with the national objective of further reforming the medical and healthcare systems, and will promote Hong Kong's development into an international health and medical innovation hub by complementing technological innovation with institutional innovation. We will fully utilise the institutional advantages of 'one country, two systems' and our professional strengths in the healthcare sector, thereby enabling the innovative medical technologies to go global and attract foreign investment, and develop new quality productive forces in biomedicine.

     "To achieve this goal, the HKSAR Government will expedite the reform of the approval mechanism for drugs and medical devices and enhance the translation of innovative biomedical research results into clinical applications, such as jointly establishing the Greater Bay Area (GBA) Clinical Trial Collaboration Platform in concerted efforts by the GBA International Clinical Trial Institute in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone and the GBA International Clinical Trials Center in the Shenzhen Park; establishing the Real-World Study and Application Centre; preparing for the establishment of the Hong Kong Centre for Medical Products Regulation to progress towards the 'primary evaluation' approach; and taking forward at full steam the preparatory work for legislating for the statutory regulation of medical devices.

     "At the same time, the HKSAR Government is also committed to developing Hong Kong into a national bridgehead for the internationalisation of Chinese medicine, including fostering international research collaboration on herb-drug interactions, promoting the development of standards, testing and scientific research of Chinese medicines through the the Government Chinese Medicines Testing Institute, as well as encouraging more large-scale international and regional conferences, exhibitions and mega events on Chinese medicine to be held in Hong Kong. The HKSAR Government will also encourage the Chinese medicine sector to make good use of policies benefitting Hong Kong, such as the arrangement of streamlining approval procedures for Hong Kong-registered traditional proprietary Chinese medicines for external use or oral use to be registered and sold on the Mainland to expedite the development of the Chinese medicine industry and open up new markets."

     Professor Lo emphasised that the HKSAR Government will continue to push forward co-operation with Guangdong Province and the Shenzhen Municipality in areas such as cross-boundary healthcare services, training of healthcare staff, medical technology exchanges and Chinese medicine development under the principles of complementarity and mutual benefits in a bid to build a "Healthy Bay Area" and further contribute to the overall development of the nation through joint endeavours.

Ends/Wednesday, April 23, 2025
Issued at HKT 20:05

NNNN